Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 17/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.48 |
| ▸ | AKT1 | P31749 | 1/20 | 0.48 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 0.47 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20618761 | 0.86 | ROCK2 (0.75) | ROCK2ROCK1AKT1CDC42BPAKDM4E | |
| SCHEMBL20611962 | 0.85 | ROCK2 (0.74) | ROCK2ROCK1AKT1CDC42BPA | |
| SCHEMBL3714084 | 0.84 | ROCK2 (0.71) | ROCK2ROCK1AKT1CDC42BPA | |
| SCHEMBL3713988 | 0.82 | ROCK2 (0.69) | ROCK2ROCK1AKT1CDC42BPA | |
| SCHEMBL3801726 | 0.82 | ROCK2 (0.69) | ROCK2ROCK1KDM4EMEN1ALDH1A1 | |
| SCHEMBL3711719 | 0.81 | ROCK2 (0.67) | ROCK2ROCK1AKT1 | |
| SCHEMBL15995961 | 0.79 | ROCK2 (0.65) | ROCK2ROCK1AKT1CDC42BPAKDM4E | |
| SCHEMBL29266032 | 0.79 | ROCK2 (0.65) | ROCK2NTRK1KDM4EMEN1ALDH1A1 | |
| SCHEMBL3806707 | 0.79 | ROCK2 (0.65) | ROCK2ROCK1CDC42BPANTRK1 | |
| SCHEMBL3723069 | 0.79 | ROCK2 (0.65) | ROCK2ROCK1KDM4EMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2961746-B1 | PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-01-03 | — | — | EP | disclosed |
| US-9828345-B2 | Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828345-B2 | Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-28 | — | — | US | disclosed |
| US-9828345-B2 | Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-28 | — | — | US | disclosed |
| US-20160002172-A1 | PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-07 | — | — | US | disclosed |
| US-20160002172-A1 | PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-07 | — | — | US | disclosed |
| US-20160002172-A1 | PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-07 | — | — | US | disclosed |
| EP-2961746-A1 | PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-01-06 | — | — | EP | disclosed |
| WO-2014134391-A1 | PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-04 | — | — | WO | disclosed |
| WO-2014134391-A1 | PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-04 | — | — | WO | disclosed |
| EP-2234618-A1 | BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS | The Scripps Research Institute (US) | 2010-10-06 | — | — | EP | disclosed |
| WO-2009079008-A1 | BENZOPYRANS AND ANALOGS AS RHO KINASE INHIBITORS | FENG YANGBO (US) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002172-A1 | PHENYLPYRAZOLE DERIVATIVES AS POTENT ROCK1 AND ROCK2 INHIBITORS | ROCK1, ROCK2, MYLK | ROCK2 2/4885ROCK1 1/4885AKT1 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.